文献速递神经肌肉病

血脂与载脂蛋白对肌萎缩侧索硬化预后的预测价值

Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis.
PubMed 文献 · Neurology · 2020-03-27

结果显示总胆固醇、低密度脂蛋白胆固醇、低密度脂蛋白胆固醇/高密度脂蛋白胆固醇比值、载脂蛋白B及载脂蛋白B/载脂蛋白AI比值每增加1个标准差均与确诊后死亡风险降低相关,按分类变量分析时也观察到剂量反应关系。结论认为血脂和载脂蛋白是肌萎缩侧索硬化的重要预后指标,应在确诊时监测。

要点

  • 总胆固醇每增加1个标准差,确诊后死亡风险比为0.60(95%CI 0.41-0.89,p=0.01)。
  • 载脂蛋白B每增加1个标准差,确诊后死亡风险比为0.62(95%CI 0.44-0.88,p=0.01)。
  • 血脂和载脂蛋白是肌萎缩侧索硬化的重要预后指标,应在确诊时监测。

核心结论

  • 血脂和载脂蛋白是肌萎缩侧索硬化的重要预后指标,应在确诊时监测。

研究设计与样本

  • 在诊断时或诊断后不久检测总胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇、甘油三酯、载脂蛋白AI、载脂蛋白B及血脂比值。
  • 以确诊后死亡为主要结局,采用Cox模型校正性别、诊断年龄、症状起病部位、诊断延迟、体重指数、ALSFRS-R评分及进展率后估计风险比。

主要发现

  • 总胆固醇每增加1个标准差与确诊后死亡风险降低相关(风险比0.60,95%CI 0.41-0.89,p=0.01)。
  • 低密度脂蛋白胆固醇每增加1个标准差与确诊后死亡风险降低相关(风险比0.64,95%CI 0.44-0.92,p=0.02)。
  • 低密度脂蛋白胆固醇/高密度脂蛋白胆固醇比值每增加1个标准差与确诊后死亡风险降低相关(风险比0.65,95%CI 0.46-0.92,p=0.02)。
  • 载脂蛋白B每增加1个标准差与确诊后死亡风险降低相关(风险比0.62,95%CI 0.44-0.88,p=0.01)。
  • 载脂蛋白B/载脂蛋白AI比值每增加1个标准差与确诊后死亡风险降低相关(风险比0.61,95%CI 0.43-0.86,p<0.01)。

临床怎么用

  • 对肌萎缩侧索硬化患者应在确诊时监测血脂和载脂蛋白,以辅助预后评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether lipids and apolipoproteins predict prognosis of patients with amyotrophic lateral sclerosis in a cohort study of 99 patients with amyotrophic lateral sclerosis who were diagnosed during 2015 to 2018 and followed up until October 31, 2018, at the Neurology Clinic in Karolinska University Hospital in Stockholm, Sweden. METHODS: Total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein AI, apolipoprotein B, and lipid ratios were measured at the time of amyotrophic lateral sclerosis diagnosis or shortly thereafter. Death after amyotrophic lateral sclerosis diagnosis was used as the main outcome. The Cox model was used to estimate hazard ratios with 95% confidence intervals of death after amyotrophic lateral sclerosis diagnosis, after controlling for sex, age at diagnosis, site of symptom onset, diagnostic delay, body mass index, Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised score, and progression rate. RESULTS: A 1-SD increase of total cholesterol (hazard ratio 0.60, 95% confidence interval 0.41-0.89, p = 0.01), low-density lipoprotein cholesterol (hazard ratio 0.64, 95% confidence interval 0.44-0.92, p = 0.02), low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio (hazard ratio 0.65, 95% confidence interval 0.46-0.92, p = 0.02), apolipoprotein B (hazard ratio 0.62, 95% confidence interval 0.44-0.88, p = 0.01), or apolipoprotein B/apolipoprotein AI ratio (hazard ratio 0.61, 95% confidence interval 0.43-0.86, p < 0.01) was associated with a lower risk of death after amyotrophic lateral sclerosis diagnosis. A dose-response relationship was also noted when these biomarkers were analyzed as categorical variables. CONCLUSIONS: Lipids and apolipoproteins are important prognostic indicators for amyotrophic lateral sclerosis and should be monitored at the diagnosis of amyotrophic lateral sclerosis.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Ingre C, Chen L, Zhan Y, et al. Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis. Neurology. 2020. PMID: 32221024. doi:10.1212/WNL.0000000000009322

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。